Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib versus crizotinib in first-line ROS1-positive advanced non-small cell lung cancer
2023-507494-18-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Entrectinib with Crizotinib (2 arms). Primary endpoint: Progression-free survival in patients with CNS metastases at baseline. Planned start Feb 2024; status: authorised.
02
Drugs
entrectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-507494-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507494-18-00.